Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
- Conditions
- Myocardial Infarction, Acute
- Registration Number
- NCT06038994
- Lead Sponsor
- Nanjing Medical University
- Brief Summary
To evaluate the prognostic value of surem TRAF3IP2 levels in patients with acute myocardial infarction
- Detailed Description
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients diagnosed with acute myocardial infarction who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the major adverse cardiac events will be evaluated.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Patients with acute myocardial infarction
- patients received coronary angiography
- invasive management within 72 h of hospital admission
- NYHA III-IV
- malignant tumor
- acute infection
- thyroid dysfunction
- Life expectancy of b1 y
- Unsuitable for PCI
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MACEs (major adverse cardiac events) 1 year MACEs were defined as a composite of cardiac death, hospitalization for myocardial infarction or heart failure
- Secondary Outcome Measures
Name Time Method hospitalization for myocardial infarction or heart failure 1 year hospitalization for myocardial infarction or heart failure
cardiac death 1 year and death due to cardiac reasons, such as myocardial infarction or heart failure
Trial Locations
- Locations (1)
Huai'an First People's Hospital
🇨🇳Huai'an, Jiangsu, China
Huai'an First People's Hospital🇨🇳Huai'an, Jiangsu, ChinaXiaozhong Yang, MD.Contact+8684922412